Madrigal Gets FDA Priority Review of Resmetirom in NASH With Liver Fibrosis
By Colin Kellaher
Madrigal Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of its lead drug candidate resmetirom for certain patients with nonalcoholic steatohepatitis, a chronic liver condition commonly known as NASH.
The West Conshohocken, Pa., clinical-stage biopharmaceutical company on Wednesday said the application covers resmetirom for the treatment of adults with NASH with liver fibrosis.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.
Madrigal said the FDA assigned a target action date of March 14, 2024, for the application, adding that the agency isn't currently planning to hold an advisory committee meeting.
Madrigal said an FDA green light would make resmetirom the first approved treatment for patients with NASH with liver fibrosis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 13, 2023 09:41 ET (13:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst